Anixa Biosciences (NASDAQ:ANIX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Anixa Biosciences (NASDAQ:ANIX) from a sell rating to a hold rating in a report issued on Saturday.

ANIX has been the subject of a number of other research reports. Zacks Research cut Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Anixa Biosciences in a research report on Monday, December 29th. Finally, D. Boral Capital restated a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a report on Friday, December 12th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $9.00.

Anixa Biosciences Trading Down 0.9%

Shares of NASDAQ ANIX opened at $3.19 on Friday. The firm has a fifty day simple moving average of $3.86 and a two-hundred day simple moving average of $3.60. The firm has a market capitalization of $106.48 million, a PE ratio of -9.11 and a beta of 0.49. Anixa Biosciences has a 12 month low of $2.33 and a 12 month high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Monday, January 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09). On average, sell-side analysts predict that Anixa Biosciences will post -0.41 earnings per share for the current year.

Hedge Funds Weigh In On Anixa Biosciences

Several institutional investors have recently made changes to their positions in the business. Bank of America Corp DE raised its position in shares of Anixa Biosciences by 1.7% during the third quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock valued at $706,000 after buying an additional 3,645 shares during the last quarter. GSA Capital Partners LLP increased its holdings in shares of Anixa Biosciences by 4.9% in the third quarter. GSA Capital Partners LLP now owns 81,897 shares of the company’s stock worth $270,000 after purchasing an additional 3,790 shares during the last quarter. Prosperity Wealth Management Inc. lifted its position in shares of Anixa Biosciences by 14.5% in the third quarter. Prosperity Wealth Management Inc. now owns 41,800 shares of the company’s stock worth $138,000 after buying an additional 5,300 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in Anixa Biosciences by 2,000.0% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock valued at $35,000 after buying an additional 10,000 shares in the last quarter. Finally, NewEdge Advisors LLC bought a new stake in Anixa Biosciences in the 2nd quarter worth approximately $33,000. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.